On September 10, 2020 Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported presentations at the following conferences during the month of September (Press release, Exicure, SEP 10, 2020, View Source [SID1234564969]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TIDES: Oligonucleotide & Peptide Therapeutics
Panel discussion: The impact of technological advances in the TIDES Space
Presented by: CEO David Giljohann
Tuesday, September 15, 2020

Panel Discussion: Streamlining the transition from discovery to manufacturing
Presented by: Vice President of Translational Research Weston Daniel
Tuesday, September 15, 2020
H.C. Wainwright 22nd Annual Global Investment Conference
Corporate update
Presented by: CEO David Giljohann
Tuesday, September 15, 2020 at 1:00pm ET
Replays of the H.C. Wainwright webcast will be available on Exicure’s website for 90 days following the webcast.